A Randomised, Open Label, Five-way Crossover Study to Assess the Systemic Exposure of Fluticasone Propionate and Salmeterol From SERETIDE/ADVAIR 250HFA MDI Alone and With AeroChamber-Max Spacer and VOLUMATIC Both in Their Washed and Unwashed States in Adult Subjects With Mild or Intermittent Asthma
Phase of Trial: Phase II
Latest Information Update: 21 Oct 2016
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary)
- Indications Asthma
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 12 Oct 2008 Status changed from active, no longer recruiting to completed.
- 12 Oct 2008 Trial phase changed from I to II as reported by ClinicalTrials.gov
- 05 Nov 2006 New trial record.